Vol 61, No 11 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Diagnostic value of BNP in suspected perimyocarditis - a preliminary report

Marcin Grabowski, Grzegorz Karpiński, Krzysztof J. Filipiak, Adam Rdzanek, Arkadiusz Pietrasik, Dominik Wretowski, Robert Rudowski, Grzegorz Opolski
Kardiol Pol 2004;61(11):455-458.
Vol 61, No 11 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Diagnosis of perimyocarditis is often very challenging. Clinical presentation includes chest pain and ECG changes which are difficult to interpret. Clinical course is usually mild, however, some patients develop heart failure symptoms and require aggressive treatment. Plasma b-type natriuretic peptide (BNP) is a marker of the heamodynamical impairment of the heart. Its diagnostic role in patients with acute perimyocarditis has not yet been examined.
Aim: To assess the usefulness of BNP measurement in the diagnosis of perimyocarditis.
Methods: The study group consisted of 14 consecutive patients (13 males, mean age 32.1±12.4 years) with suspected perimyocarditis (history of influenza, typical symptoms, ECG and echocardiographic results as well as myocardial necrotic markers). Plasma BNP was assessed at bedside at the time of admission.
Results: Plasma BNP, measured in 12 patients, was 163±154 pg/mL (max. 519 pg/mL) and exceeded upper normal level in 6 (50%) patients. When normal levels were adjusted for age and gender, 9 (80%) patients had elevated BNP. One patient had heart failure symptoms and a BNP level of 205 pg/mL. In all 4 patients who had transient myocardial contractility disturbances, detected by echocardiography, BNP level exceeded 100 pg/mL.
Conclusions: BNP level is increased in some patients with acute perimyocarditis. BNP elevation is probably associated with haemodynamical stress caused by transient contractility abnormalities. Diagnostic and prognostic role of BNP in acute perimyocarditis requires further studies.

Abstract

Background: Diagnosis of perimyocarditis is often very challenging. Clinical presentation includes chest pain and ECG changes which are difficult to interpret. Clinical course is usually mild, however, some patients develop heart failure symptoms and require aggressive treatment. Plasma b-type natriuretic peptide (BNP) is a marker of the heamodynamical impairment of the heart. Its diagnostic role in patients with acute perimyocarditis has not yet been examined.
Aim: To assess the usefulness of BNP measurement in the diagnosis of perimyocarditis.
Methods: The study group consisted of 14 consecutive patients (13 males, mean age 32.1±12.4 years) with suspected perimyocarditis (history of influenza, typical symptoms, ECG and echocardiographic results as well as myocardial necrotic markers). Plasma BNP was assessed at bedside at the time of admission.
Results: Plasma BNP, measured in 12 patients, was 163±154 pg/mL (max. 519 pg/mL) and exceeded upper normal level in 6 (50%) patients. When normal levels were adjusted for age and gender, 9 (80%) patients had elevated BNP. One patient had heart failure symptoms and a BNP level of 205 pg/mL. In all 4 patients who had transient myocardial contractility disturbances, detected by echocardiography, BNP level exceeded 100 pg/mL.
Conclusions: BNP level is increased in some patients with acute perimyocarditis. BNP elevation is probably associated with haemodynamical stress caused by transient contractility abnormalities. Diagnostic and prognostic role of BNP in acute perimyocarditis requires further studies.
Get Citation

Keywords

b-type natriuretic peptide - perimyocarditis

About this article
Title

Diagnostic value of BNP in suspected perimyocarditis - a preliminary report

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 61, No 11 (2004)

Pages

455-458

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2004;61(11):455-458.

Keywords

b-type natriuretic peptide - perimyocarditis

Authors

Marcin Grabowski
Grzegorz Karpiński
Krzysztof J. Filipiak
Adam Rdzanek
Arkadiusz Pietrasik
Dominik Wretowski
Robert Rudowski
Grzegorz Opolski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl